RAPIBLOC 300 mg, powder for solution for infusion bottle, 50 ml
Active ingredients: Landiolol hydrochloride, Landiolol
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Powder for solution for infusionbottle, 50 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- RAPIBLOC 300 mg, poudre pour solution pour perfusion
- Pharmaceutical form
- poudre pour solution pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon(s) en verre de 50 ml
- Marketing authorisation holder
- AMOMED PHARMA (AUTRICHE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 12 Jun 2018
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67004301CIP75502691CIP133400955026914Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE DE LANDIOLOLpoudre | 300 mg · un flacon de poudre | SA |
| LANDIOLOLpoudre | 280 mg · un flacon de poudre | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.